Skip main navigation

Home > Search Results

Main contents starts here

Search Results

81 - 100 of about 337

Total 337 documents found.

  •  
  • Takeda Pharmaceutical Company Limited TakedaTakeda''s Approach to Building A World Classs Approach to Building A World Class Pharmaceutical Company in an IncreasinglyPharmaceutical Company in an Increasingly Challenging EnvironmentChallenging Environment Yasuchika Hasegawa, President & COO Takeda Pharmaceutical Company Limited February 9, 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies and results for the future. All forward-looking statements are based on judgements derived from the information available to the Company at this time. Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this presentation. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company's business; competitive pressure; relative laws and regulations; product developm
  • Reports & Publications
  • This page is a library which contains Takeda’s quarterly financial results, R&D activities, annual reports and booklets.
  • Takeda Appoints Two Executive-level Personnel from Outside the Company June 28, 2010
  • Osaka, Japan, June 28, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced at the extraordinary Board of Directors’ Meeting held on June 25th, 2010, it resolved to appoint Frank Morich, M.D., Ph.D. as Executive Vice President (EVP), International Operations, effective October 1, 2010, and also to appoint Mr. Haruhiko Hirate as Corporate Officer, Senior Vice President, effective July 1, 2010.
  • FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000099 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market
  • The Takeda-Plan Healthcare Access Program Activities in Japan and Asia The Plan Japan, which assists children in developing countries, is a member of Plan International, a global NGO registered by the United Nations that is active in 65 countries throughout the world. In August 2009, Takeda partnered with Plan Japan to start the Takeda-Plan Healthcare Access Program. Improving the health of children in developing countries requires measures that match the differing needs of each region. There are often significant differences from country to country concerning needs involving public hygiene, nutrition, healthcare services and disease prevention. The Takeda-Plan program will operate in China, Indonesia, the Philippines and Thailand. The aim is to conduct extensive activities for giving children better access to healthcare. All four individual projects to take place as part of the Takeda-Plan program will help contribute to achieving the Millennium Development Goals* that were established by the United Nations
  • 104 Consolidated Balance Sheets Takeda Pharmaceutical Company Limited and Subsidiaries Years ended March 31, 2009 and 2008 Millions of yen Thousands of U.S. dollars (Note 1) ASSETS 2009 2008 2009 Current assets: Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 758,082 1,613,240 $ 7,735,531 Marketable securities (Note 5) . . . . . . . . . . . . . . . . . . . . . . . . . 699 45,453 7,133 Short-term investments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,300 Trade notes and accounts receivable: Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,896 15,212 152,000 Accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284,157 224,537 2,899,561 Due from affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,319 8,440 33,867 Allowance for doubtful receivables . . . . . . . . . . . . . . . . . . . . (924) (899) (9,429) Total . . . . . . . . . . . . . . . . . . .
  • 48 Major Categories of Items Procured Building sound and fair relationships as equals with suppliers based on the Takeda Compliance Program for Globalization Committed to Sound and Fair Business Relationships Building supplier relationships in the spirit of "soundness and fairness based on a partnership as equals" is of particular importance in the pharmaceutical industry. Unlike other industries that have a large number of suppliers, successful pharmaceutical operations require partnerships only with companies capable of consistently supplying raw materials, equipment and other products of high quality that comply with strict government regulations for manufacturing and sales of pharmaceuticals. Procuring materials for factories, research centers and other business sites is the responsibility of the General Purchasing Department. Members of the department establish sound and fair relationships in line with Takeda's Guidance for Purchasing Affairs. These guidelines, in turn, are based on the Basic Purchasing
  • 33 RelationshipwithOurStakeholders EnvironmentRelationship with Relationship with Environment Takeda's Major Environmental Protection Policies and Achievements in Fiscal 2008 Fiscal 2008 AchievementsPoliciesTheme Maintained a legal compliance framework by using periodic environmental monitoring based on internal standards, which are more stringent than those of laws and regulations Establish framework for legal compliance and comply with internal standards FY2008 CO2 emissions of 231,000 tons were 35% less than in FY2005 PRTR (Pollutant Release and Transfer Register) chemical substances released in FY2008 amounted to 27 tons, 40% less than in FY2005 Initial risk assessments were performed, confirming that no manufacturing plant releases chemical substances that significantly affect the environment Through the zero-emission activities, FY2008 waste for final disposal amounted to 74 tons, 75% less than in FY2004 Conducted compliance education programs that included the use of the company intranet and complianc
  • FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000088 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market function in each
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 23 - 4. Consolidated Financial Statements (1) Consolidated Balance Sheets (Millions of yen) Fiscal 2007 (As of March 31, 2008) Fiscal 2008 (As of March 31, 2009) ASSETS Current assets Cash and deposits 239,528 229,533 Notes and accounts receivable 248,189 302,372 Marketable securities 1,445,465 529,248 Inventories 116,131 Merchandise and products 60,792 Work in process 35,327 Raw materials and supplies 35,539 Deferred tax assets 140,962 218,174 Other current assets 54,415 65,523 Allowance for doubtful receivables (899) (924) Total current assets 2,243,792 1,475,584 Fixed assets Tangible fixed assets Buildings and structures 105,799 103,546 Machinery, equipment and carriers: 49,158 48,079 Tools and fixtures 9,537 8,877 Land 61,835 63,012 Lease assets 17,026 Construction in progress 9,804 17,954 Total tangible fixed assets 236,134 258,493 Intangible fixed assets Goodwill 3,656 284,446 Patents 454,137 Other intangib
  • 82 Consolidated Balance Sheets Takeda Pharmaceutical Company Limited and Subsidiaries Years ended March 31, 2008 and 2007 Millions of yen Thousands of U.S. dollars (Note 1) ASSETS 2008 2007 2008 Current assets: Cash and cash equivalents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,613,240 1,647,694 $16,132,400 Marketable securities (Note 3). . . . . . . . . . . . . . . . . . . . . . . . . . 45,453 92,342 454,530 Short-term investments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,300 59,900 263,000 Notes and accounts receivable Trade notes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15,212 20,695 152,120 Trade accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224,537 232,639 2,245,370 Due from affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,440 8,641 84,400 Allowance for doubtful receivables . . . . . . . . . . . . . . . . . . . . (899) (535) (8,990) Total . . . . . . . . . . . . . .
  • 13 ENHANCEMENT OF THE TAKEDA GROUP'S RISK MANAGEMENT STRUCTURE As part of the corporate governance of the Takeda group, preventing and precisely responding to emergency situations are important, and Takeda considers that it is necessary to establish and enhance a risk management structure, along with the fulfillment of internal controls, such as a group-wide audit, as well as promotion of compliance. On the risk management, responses in the manner of fairness and integrity are important for personal and economic safety in the view point of responsibility toward stakeholders, such as shareholders, customers, suppliers, employees, community and society. As part of such efforts, Takeda addresses the establishment of a Business Continuity Plan (BCP) in order to prevent the interruption of business activities or, even if shut down, to restart the activities at the earliest opportunity, in the event of any accident or disaster. In accordance with "Takeda Group Crisis Management Guidelines," which is to clarify and
  • Takeda implements measures in all areas of its business, with "Basic Principles on the Environment" as its benchmark. EnvironmentRelationship with Takeda Annual Report 200642 Basic Principles on the Environment See Takeda's website for details. http://www.takeda.com/csr/environment/principle.html 1. Overall Policy Give serious consideration to the impact on the environment in every aspect of corporate activities, including R&D, production, distribution, marketing, procurement and clerical works, and make the best efforts to conserve and improve the environment. 2. Efficient Utilization of Resources and Minimization of Waste Conserve energy and other resources, and actively pursue waste minimization and resource recycling. 3. Assessment of Environmental Impact from Products and Manufacturing Processes When developing new products and processes, evaluate the impact on the environment in advance, during development, and periodically after commercialization. Consider the entire business cycle from procurement of
  • Takeda Annual Report 20064 Chairman KunioTakeda / President Yasuchika Hasegawa SUMMARY OF ACCOMPLISHMENTS IN FISCAL 2005 ACHIEVING A RECORD HIGH IN NET SALES, OPERATING INCOME AND CURRENT NET INCOME Takeda Annual Report 2006 5 Setting our management philosophy, "Takeda-ism" as the basis of business, we strive toward being a "world-class pharmaceutical company with Japanese origin." Net sales in fiscal 2005, which was the final year of the 2001-2005 Medium-Term Management Plan, reached 1.2122 trillion (a 7.9 percent increase over the previous year). Net sales of the pharmaceutical business reached 1.0745 trillion (a 10.7 percent increase over the previous year), which resulted in an increase of its ratio to total sales up to 88.6 percent from 86.4 percent in the previous year, contributing largely to overall increased revenue. Sales of the ethical drug business, which is our core business category, achieved 1.0191 trillion (an 11.4 percent increase over the previous year), exceeding the trillion yen mark for
  • FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000066 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2039 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/english/financial/index.html 2006-2010 Medium-Term Management Plan 〜 Growth toward a World-class Pharmaceutical Company with Japanese Origin 〜 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect sales of in-house ethical products of 2 trillion yen in fiscal 2015 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market function in each region with self-sustaining
  • FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000066 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Management Plan 〜 Growth toward a World-class Pharmaceutical Company with Japanese Origin 〜 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect sales of in-house ethical products of 2 trillion yen in fiscal 2015 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market function in each region with self-sustaining and appropriate operatio
  • - 1 - Consolidated Financial Statements for the Fiscal Year Ended March 31, 2006 May 11, 2006 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya 1-1, Doshomachi 4-chome (First section of each) Chuo-ku, Osaka 540-8645, Japan Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Code number: 4502 Representative: Yasuchika Hasegawa, President and COO Board of Directors meeting: May 11, 2006 Contact: Toyoji Yoshida, Director Use of U.S. accounting standards: No Tel: +81-6-6204-2060 +81-3-3278-2039 1. Results for Fiscal 2005 (April 1, 2005 - March 31, 2006) (1) Sales and Income All amounts are rounded to the nearest million yen. Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Fiscal 2005 Fiscal 2004 1,212,207 1,122,960 7.9 3.4 402,809 385,278
  • 33 Basic Principles on the Environment See Takeda's web site for details. Takeda Corporate Social Responsibility Report 2005 Basic Principles on the Environment - Actions and Achievements Takeda has developed basic environmental principles in all areas of its business. Takeda's Answer 1.Overall Policy Give serious consideration to the impact on the environment in every aspect of corporate activities, including R&D, production, distribution, marketing, procurement and clerical works, and make the best efforts to conserve and improve the environment. 2.Efficient Utilization of Resources and Minimization of Waste Conserve energy and other resources, and actively pursue waste minimization and resource recycling. 3.Assessment of Environmental Impact from Products and Manufacturing Processes When developing new products and processes, evaluate the impact on the environment in advance, during development, and periodically after commercialization. Consider the entire business cycle from procurement of raw materials

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top